Bluejay Diagnostics, Inc. (NASDAQ:BJDX) Short Interest Down 50.9% in January

Bluejay Diagnostics, Inc. (NASDAQ:BJDX) was the target of a significant decline in short interest in the month of January. As of January 15th, there was short interest totalling 13,300 shares, a decline of 50.9% from the December 31st total of 27,100 shares. Based on an average trading volume of 652,600 shares, the days-to-cover ratio is presently 0.0 days. Currently, 2.4% of the shares of the company are short sold.

Bluejay Diagnostics Trading Up 0.8 %

NASDAQ BJDX opened at $3.96 on Wednesday. The business’s 50 day moving average is $3.94 and its two-hundred day moving average is $8.86. Bluejay Diagnostics has a 12-month low of $3.03 and a 12-month high of $386.72.

Bluejay Diagnostics (NASDAQ:BJDX) last issued its earnings results on Thursday, November 7th. The company reported ($8.00) earnings per share for the quarter.

Institutional Trading of Bluejay Diagnostics

A hedge fund recently raised its stake in Bluejay Diagnostics stock. Anson Funds Management LP boosted its holdings in Bluejay Diagnostics, Inc. (NASDAQ:BJDX) by 359.3% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 319,280 shares of the company’s stock after acquiring an additional 249,770 shares during the period. Anson Funds Management LP owned 1.93% of Bluejay Diagnostics worth $41,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 18.47% of the company’s stock.

Bluejay Diagnostics Company Profile

Bluejay Diagnostics, Inc, a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components.